ELIGARD® utilises the unique ATRIGEL® delivery system for controlled release of leuprolide over time1-3 ELIGARD® offers 3 and 6-month dosing options to suit patient needs1-3 Dosing Intervals Approximate Injection Volume Per Dosage Dosage 0.375 ml 3 MONTHS 22.5 mg 0.375 ml 6 MONTHS 45 mg Suspension ELIGARD® is injected into the subcutaneous space. Rapidly Formed Solid Polymers respond to water by precipitating and trapping leuprolide acetate in a solid implant. Controlled Drug Release Over Time Biodegradable polymers degrade by hydrolysis, slowly releasing leuprolide acetate. For full prescribing information refer to the Professional Information (PI) approved by the South African Health Products Regulatory Authority. S4 ELIGARD® Registration number: A39/26/0649. Composition: One syringe contains the ATRIGEL® Delivery System, and the other contains lyophilised leuprolide acetate. The second syringe contains lyophilised leuprolide acetate and is designed to deliver 22,5 mg leuprolide acetate at the time of subcutaneous injection. S4 ELIGARD® Registration number: A39/26/0651. Composition: One syringe contains the ATRIGEL® Delivery System, and the other contains lyophilised leuprolide acetate. The second syringe contains lyophilised leuprolide acetate and is designed to deliver 45 mg leuprolide acetate at the time of subcutaneous injection. Reference: 1. South African Approved Professional Information (PI), 3 March 2023. 2. Schulman C. et al. Expert opinion on 6-monthly luteinizing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100(Suppl. 1):1-5 3. ATRIGEL® delivery system [online]; Available from: http://eligardhcp.com/atrigel-delivery. Accessed on 3 October 2023. 4. Crawford DE. et al. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol. (2015) 11(9):1465-1474. 5. Meani D. et al. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol 2018, Vol. 10(2) 51–63. Applicant: Key Oncologics (Pty) Ltd. Reg. No. 95/013825/07. 39 11th Avenue, Houghton Estate, Johannesburg, 2198, South Africa. Tel: +27 11 483 0060/5. Email: key@icon.co.za. www.keyoncologics.co.za. To report an adverse event or product complaint please email: safety@keyoncologics.co.za or phone: +27 79 471 1771. 22357T. 10/2023. ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.1 Benefits of Subcutaneous Injections4,5 • Greater number of potential injection sites • A shorter needle designed to reach no further than the subcutaneous space • Smaller drug volumes • Decreased muscle mass is not a concern • Less injection site discomfort compared with intramuscular delivery Areas with sufficient subcutaneous tissue
RkJQdWJsaXNoZXIy NTIyOTQ=